Voice disorder in systemic lupus erythematosus

被引:9
作者
de Macedo, Milena S. F. C. [1 ,2 ]
Costa, Kaue M. [3 ]
da Silva Filho, Manoel [1 ]
机构
[1] Fed Univ Para, Inst Biol Sci, Belem, Para, Brazil
[2] Ophir Loyola Hosp, Belem, Para, Brazil
[3] Goethe Univ, Interdisciplinary Ctr Neurosci, Inst Neu rophysiol, Frankfurt, Germany
来源
PLOS ONE | 2017年 / 12卷 / 04期
关键词
QUALITY-OF-LIFE; THE-LITERATURE; DAMAGE INDEX; DYSPHONIA; THERAPY; REFLUX; DISEASE;
D O I
10.1371/journal.pone.0175893
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Systemic lupus erythematosus (SLE) is a chronic disease characterized by progressive tissue damage. In recent decades, novel treatments have greatly extended the life span of SLE patients. This creates a high demand for identifying the overarching symptoms associated with SLE and developing therapies that improve their life quality under chronic care. We hypothesized that SLE patients would present dysphonic symptoms. Given that voice disorders can reduce life quality, identifying a potential SLE-related dysphonia could be relevant for the appraisal and management of this disease. We measured objective vocal parameters and perceived vocal quality with the GRBAS (Grade, Roughness, Breathiness, Asthenia, Strain) scale in SLE patients and compared them to matched healthy controls. SLE patients also filled a questionnaire reporting perceived vocal deficits. SLE patients had significantly lower vocal intensity and harmonics to noise ratio, as well as increased jitter and shimmer. All subjective parameters of the GRBAS scale were significantly abnormal in SLE patients. Additionally, the vast majority of SLE patients (29/36) reported at least one perceived vocal deficit, with the most prevalent deficits being vocal fatigue (19/36) and hoarseness (17/36). Self-reported voice deficits were highly correlated with altered GRBAS scores. Additionally, tissue damage scores in different organ systems correlated with dysphonic symptoms, suggesting that some features of SLE-related dysphonia are due to tissue damage. Our results show that a large fraction of SLE patients suffers from perceivable dysphonia and may benefit from voice therapy in order to improve quality of life.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Vasculitis in Systemic Lupus Erythematosus
    Barile-Fabris, L.
    Hernandez-Cabrera, M. F.
    Barragan-Garfias, J. A.
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (09)
  • [2] Glucocorticoids in systemic lupus erythematosus
    Mosca, M.
    Tani, C.
    Carli, L.
    Bombardieri, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (05) : S126 - S129
  • [3] Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis
    Beckwith, Hannah
    Lightstone, Liz
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 250 - 254
  • [4] Major depressive disorder and disease activity in systemic lupus erythematosus
    Nery, Fabiano G.
    Borba, Eduardo F.
    Hatch, John P.
    Soares, Jair C.
    Bonfa, Eloisa
    Neto, Francisco Lotufo
    COMPREHENSIVE PSYCHIATRY, 2007, 48 (01) : 14 - 19
  • [5] One year in review 2015: systemic lupus erythematosus
    Mirabelli, G.
    Cannarile, F.
    Bruni, C.
    Vagelli, R.
    De Luca, R.
    Carli, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : 414 - 425
  • [6] Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
    Mina, Rina
    Klein-Gitelman, Marisa S.
    Nelson, Shannen
    Eberhard, B. Anne
    Higgins, Gloria
    Singer, Nora G.
    Onel, Karen
    Tucker, Lori
    O'Neil, Kathleen M.
    Punaro, Marilynn
    Levy, Deborah M.
    Haines, Kathleen
    Martini, Alberto
    Ruperto, Nicolino
    Lovell, Daniel
    Brunner, Hermine I.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) : 401 - 406
  • [7] Pulmonary hypertension in systemic lupus erythematosus
    Schreiber, Benjamin E.
    Connolly, Michelle J.
    Coghlan, J. Gerry
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2013, 27 (03): : 425 - 434
  • [8] A glimpse into the future of systemic lupus erythematosus
    Aringer, Martin
    Alarcon-Riquelme, Marta E.
    Clowse, Megan
    Pons-Estel, Guillermo J.
    Vital, Edward M.
    Dall'Era, Maria
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [9] Belimumab for the management of systemic lupus erythematosus
    Lutalo, Pamela M. K.
    D'Cruz, David P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (07) : 957 - 963
  • [10] Systemic lupus erythematosus
    Kaul, Arvind
    Gordon, Caroline
    Crow, Mary K.
    Touma, Zahi
    Urowitz, Murray B.
    van Vollenhoven, Ronald
    Ruiz-Irastorza, Guillermo
    Hughes, Graham
    NATURE REVIEWS DISEASE PRIMERS, 2016, 2